{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:33:50Z","timestamp":1786354430175,"version":"build-2736575974"},"reference-count":7,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.chest.2025.12.063","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:18:35Z","timestamp":1786353515000},"page":"320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rebuttal From Dr van Ingen"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2025.12.063_bib1","first-page":"315","article-title":"Counterpoint: Is monitoring drug levels clinically useful in the management of patients with nontuberculous mycobacterial lung disease? No","volume":"170","author":"Epstein","year":"2026","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2025.12.063_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1734-1140(09)70140-9","article-title":"Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects","volume":"61","author":"He","year":"2009","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.chest.2025.12.063_bib3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/clinids\/24.5.958","article-title":"Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease","volume":"24","author":"Brown","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.chest.2025.12.063_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.chest.2025.12.063_bib5","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/AAC.00770-16","article-title":"Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease","volume":"60","author":"Jeong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.chest.2025.12.063_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2025.12.063_bib7","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/AAC.02854-15","article-title":"Azithromycin dose to maximize efficacy and suppress acquired drug resistance in pulmonary Mycobacterium avium disease","volume":"60","author":"Deshpande","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922600454X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922600454X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:18:40Z","timestamp":1786353520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236922600454X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S001236922600454X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.063","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rebuttal From Dr van Ingen","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.02.048","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.062","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}